GlassScriptPhysician profile
Judith Duran
NPI 1710726906
$3,990.20
in general payments reported to CMS, 2019-2025
23 companies · $2,273 in 2025
The $2,273 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,717 · 2025: $2,273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,895 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,895.21 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $996.94 | 2024-2025 | |
| Janssen Biotech, INC. | $369.85 | 2024-2025 | Tremfya |
| Ucb, INC. | $322.48 | 2024-2025 | Bimzelx |
| Lilly USA, LLC | $290.21 | 2024-2025 | Taltz, Ebglyss, Olumiant |
| Regeneron Healthcare Solutions, INC. | $248.80 | 2024-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $237.57 | 2024-2025 | |
| Incyte Corporation | $236.79 | 2024-2025 | Opzelura |
| Galderma Laboratories, L.P. | $223.31 | 2024-2025 | Nemluvio |
| E.R. Squibb & Sons, L.L.C. | $189.47 | 2024-2025 | Sotyktu |
| Botanix Sb INC | $136.85 | 2025 | Sofdra |
| Pfizer INC. | $124.47 | 2024-2025 | |
| Arcutis Biotherapeutics, INC. | $106.38 | 2024-2025 | Zoryve |
| Genzyme Corporation | $95.91 | 2024-2025 | |
| Dermavant Sciences, INC. | $89.88 | 2024 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $81.19 | 2024-2025 | Jublia, Cabtreo, Arazlo |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $49.62 | 2024-2025 | Klisyri |
| Leo Pharma INC. | $39.25 | 2024 | Adbry |
| Organon LLC | $32.55 | 2025 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.25 | 2024 | Spevigo |
| Lnhc, INC | $24.21 | 2025 | Zelsuvmi |
| Journey Medical Corporation | $24.13 | 2024 | |
| Amgen INC. | $19.58 | 2025 | Otezla |
| Sun Pharmaceutical Industries INC. | $19.51 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Judith Duran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.